secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950142-22-002532
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Dr. Jonathan Isaacsohn as Chair of the Board
----------------------------------------------------------------------

- Dr. Jonathan Isaacsohn appointed as member and Chair of Board effective August 9, 2022.
- He is President and CEO of CinRx Pharma, LLC; appointment per July 22, 2022 stock purchase agreement.
- Annual cash compensation of $70,000 plus annual equity grant of 50,000 options; initial grant of 50,000 options on appointment.
- Dr. Isaacsohn has over 25 years in drug development; served as CMO of Teva Pharmaceutical Industries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002532/0000950142-22-002532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002532/eh220279180_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-002532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer